Find information on Industry Analysis Report

Posts tagged ‘Disease’

Report on Lysosomal Storage Disease Partnering 2007-2012

The Lysosomal Storage Disease Partnering 2007-2012 report provides understanding and access to the lysosomal storage disease partnering deals and agreements entered into by the worlds leading healthcare companies.

* Trends in lysosomal storage disease partnering deals
* Top lysosomal storage disease deals by value
* Deals listed by company A-Z, industry sector, stage of development, technology type

Description
Lysosomal Storage Disease Partnering 2007-2012 provides understanding and access to the lysosomal storage disease partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of lysosomal storage disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lysosomal storage disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 20 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of lysosomal storage disease partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in lysosomal storage disease partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading lysosomal storage disease deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of lysosomal storage disease partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of lysosomal storage disease technologies and products.

For more information kindly visit :
Report on Lysosomal Storage Disease Partnering 2007-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Advertisements

Error-Proof Entry, Expert Positioning, and Exploding Growth

Your Advantage
The potential medical advances made possible from the use of embryonic stem cells (ESC) are huge. These stem cells are able to develop into any of over 200 different cell types. So it’s no surprise that the scientific research community is enthusiastically exploring all possibilities. http://www.bharatbook.com/stem-cells-market-research-reports/error-proof-entry-expert-positioning-and-exploding-growth-in-embryonic-stem-cell-products.html

And where there is significant and growing interest from scientists, there is an opportunity for a company like yours to increase revenue from supplying stem cell products. There is no doubt it’s an exciting market in which to expand your product range. But with embryonic stem cells there are serious market entry barriers to consider – namely a complex intellectual property scene.
This report will help you understand the market entry challenges you face and give you the expert advice to overcome them. Use it to out-compete your rivals in this expanding and highly profitable market. Market Analysis

An Expanding and Highly Profitable Market
Embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin’s Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.

This market research report explores the complex IP landscape affecting development of embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives, such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species. This report will give you a fuller, more complete understanding of the complex IP situation in the embryonic stem cell market.

For more information kindly visit :
Error-Proof Entry, Expert Positioning, and Exploding Growth

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
https://twitter.com/#!/bharatbook

Tag Cloud